
Pharma Business - February 12, 2025
Lundbeck’s potential treatment for MSA receives Fast Track Designation
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Acquisition - February 10, 2025
Pharming completes bid for Abliva
Pharming Technologies declares unconditional and completes the recommended cash offer to the shareholders of Abliva and extends the acceptance period.

Financing - February 7, 2025
Herantis Pharma raises EUR 5.2 million
The company has carried out an offering of new shares in a directed share issue to institutional and other qualified investors and raises gross proceeds of EUR 5.2 million.

Pharma Business - February 3, 2025
AstraZeneca’s Imfinzi recommended for approval in the EU
AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).

Pharma Business - January 29, 2025
AstraZeneca’s Enhertu approved in the US
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies.

Pharma Business - January 29, 2025
Vicore Pharma granted Fast Track designation from the FDA
The United States Food and Drug Administration (FDA) has granted Fast Track designation to the company's lead candidate buloxibutid.